94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Immunol.
Sec. Molecular Innate Immunity
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1593729
Pulmonary Fibrosis Through the Prism of NLRP3 Inflammasome: Mechanistic Pathways and Prospective Therapeutic Innovations
Provisionally accepted- 1Department of Critical Care Medicine, The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China
- 2Department of Critical Care Medicine, The Obstetrics & Gynecology Hospital of Fudan University, Yangtze River Delta Integration Demonstration Zone (QingPu), Shanghai, China
- 3Department of Cell Biology, Navy Medical University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Pulmonary fibrosis is a disease that severely affects the patients' life quality, characterized by lung tissue remodeling and functional impairment. Recent research has found that the NLRP3 inflammasome plays an important role in the pathogenesis of pulmonary fibrosis. Although existing researches have revealed the potential role of NLRP3 in pulmonary fibrosis, many mysteries still remain regarding its specific mechanisms and clinical applications. This article aims to review the mechanisms of action of NLRP3 in pulmonary fibrosis, related signaling pathways, and the latest research progress on its potential as a therapeutic target, in hopes of providing new ideas and directions for future clinical treatment.
Keywords: NLRP3 inflammasome, Pulmonary Fibrosis, cellular signaling, inhibitors of NLRP3 inflammasome, therapeutic strategies
Received: 14 Mar 2025; Accepted: 14 Apr 2025.
Copyright: © 2025 Wang, Xie, Cao, Yu and Dai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Qingqing Dai, Department of Critical Care Medicine, The Obstetrics & Gynecology Hospital of Fudan University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.